ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

9:00AM-11:00AM: Abstract Number: 0573

Presence of Mediterranean Fever Gene Variants Provides Protection from the Development of Lupus Nephritis in Patients with Systemic Lupus Erythematosus

(0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0350

Presentation, Management, and Outcomes of Systemic JIA-Associated Lung Disease: A Single Center Experience

(0345–0379) Pediatric Rheumatology – Clinical Poster I: JIA

9:00AM-11:00AM: Abstract Number: 0634

Prevalence and Associations of Anaemia in Systemic Sclerosis Patients in a National Observational Cohort; Results from the Australian Scleroderma Cohort Study

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0305

Prevalence and Clinical Significance of anti-Ro52 Antibodies in Antisynthetase Syndrome

(0283–0307) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 0707

Prevalence and Distribution of Vascular Calcifications at CT Scan in Patients with Large Vessel Vasculitis and Patients with Lymphoma: A Matched Cross-sectional Study

(0691–0721) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0138

Prevalence and Incidence of Sjögren’s Syndrome: A Systematic Literature Review

(0117–0144) Epidemiology & Public Health Poster I

9:00AM-11:00AM: Abstract Number: 0630

Prevalence and Risk Factors for Systemic Sclerosis Digital Ischemic Complications in the Collaborative National Quality and Efficacy Registry

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0647

Prevalence and Risk Factors of Left Ventricular Diastolic Dysfunction in Systemic Sclerosis: Insights from New Echocardiographic Parameters

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0615

Prevalence of Barrett’s Esophagus in Patients with Systemic Sclerosis

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0475

Prevalence of Endometriosis and Polycystic Ovarian Syndrome in Patients with Rheumatic Diseases in the United States

(0460–0479) Reproductive Issues in Rheumatic Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0395

Prevalence of Objectively Measured Sleep Disturbance in Rheumatoid Arthritis (RA)

(0380–0422) RA – Diagnosis, Manifestations, and Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0409

Prevalence of Pulmonary Manifestations in Patients with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, and Peripheral Spondyloarthritis

(0380–0422) RA – Diagnosis, Manifestations, and Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0495

Prevalence of Undiagnosed Inflammatory Bowel Disease in Patients with Spondyloarthritis: EISER Study

(0483–0509) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: PsA

9:00AM-11:00AM: Abstract Number: 0356

PRINTO Provisional Enthesitis/Spondylitis-Related JIA Criteria: Performance in Youth Classified as Axial Disease in Juvenile Spondyloarthritis

(0345–0379) Pediatric Rheumatology – Clinical Poster I: JIA

9:00AM-11:00AM: Abstract Number: 0643

Progression of Interstitial Lung Disease in Systemic Sclerosis Does Not Predict Further Progression

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].